The estimated Net Worth of Gene G. Kinney is at least $4.42 Milione dollars as of 17 May 2023. Gene Kinney owns over 45,000 units of Prothena plc stock worth over $1,209,607 and over the last 12 years he sold PRTA stock worth over $0. In addition, he makes $3,213,350 as President, Chief Executive Officer e Director at Prothena plc.
Sign up
Gene Kinney PRTA stock SEC Form 4 insiders trading
Gene has made over 15 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of PRTA stock worth $1,341,450 on 17 May 2023.
The largest trade he's ever made was exercising 45,000 units of Prothena plc stock on 17 May 2023 worth over $1,341,450. On average, Gene trades about 7,984 units every 106 days since 2013. As of 17 May 2023 he still owns at least 57,793 units of Prothena plc stock.
You can see the complete history of Gene Kinney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gene Kinney biography
Dr. Gene G. Kinney Ph.D. serves as President, Chief Executive Officer, Director of the Company., is President, Chief Executive Officer, Director of the Company. Prior to that, he was our Chief Operating Officer for part of 2016, and prior to that he was our Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney was Vice President, Pharmacology and then Senior Vice President of Pharmacological Sciences at Elan Pharmaceuticals, Inc.; while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol-Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on our Board since 2016.
What is the salary of Gene Kinney?
As the President, Chief Executive Officer e Director of Prothena plc, the total compensation of Gene Kinney at Prothena plc is $3,213,350. There are 1 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
How old is Gene Kinney?
Gene Kinney is 51, he's been the President, Chief Executive Officer e Director of Prothena plc since 2016. There are 15 older and 9 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
What's Gene Kinney's mailing address?
Gene's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at Prothena plc
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... e Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
What does Prothena plc do?
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
What does Prothena plc's logo look like?
Complete history of Gene Kinney stock trades at Prothena plc
Prothena plc executives and stock owners
Prothena plc executives and other stock owners filed with the SEC include:
-
Wagner Zago,
Chief Scientific Officer -
Gene Kinney,
President, Chief Executive Officer, Director -
Michael Malecek,
Chief Legal Officer and Company Secretary -
Tran Nguyen,
Chief Financial Officer, Chief Operating Officer -
Carol Karp,
Chief Regulatory Officer -
Radhika Tripuraneni,
Chief Development Officer -
Dr. Gene G. Kinney Ph.D.,
Pres, CEO & Director -
Dr. Hideki Garren M.D., Ph.D.,
Chief Medical Officer -
Tran B. Nguyen M.B.A.,
CFO & Chief Strategy Officer -
Carol D. Karp,
Chief Regulatory Officer -
Michael J. Malecek,
Chief Legal Officer & Company Sec. -
Brandon S. Smith,
Chief Operating Officer -
Paula Cobb,
Independent Director -
Lars Ekman,
Independent Chairman of the Board -
Dennis Selkoe,
Independent Director -
Shane Cooke,
Independent Director -
Richard Collier,
Independent Director -
Christopher Henney,
Independent Director -
K. Anders Harfstrand,
Independent Director -
Brandon Smith,
Chief Business Officer -
Oleg Nodelman,
Independent Director -
Karin Walker,
Chief Accounting Officer, Controller -
Dr. Radhika Tripuraneni M.D., M.P.H.,
Chief Devel. Officer -
Dr. Hideki Garren,
Chief Medical Officer -
Dr. Radhika Tripuraneni M.P.H., M.D.,
Chief Devel. Officer -
Jennifer Zibuda,
Director of Investor Relations & Communication -
Dr. Wagner M. Zago,
Chief Scientific Officer -
Karin L. Walker CPA, CPA,
Chief Accounting Officer & Controller -
Sarah B. Noonberg,
Chief Medical Officer -
Arthur W Homan,
Chief Legal Officer -
Tara Nickerson,
Chief Business Officer -
Martin Koller,
Chief Medical Officer -
Capital, Llc Eco R1,
10% owner -
Sanjiv Patel,
-
Co Plc Elan Corp Plc Elan S...,
-
Dale B. Schenk,
President and CEO -
John Randall Fawcett,
Controller -
David B. Mc Ninch,
Chief Commercial Officer -
William H. Jr. Dunn,
-
Helen Susan Kim,
-
Daniel G Welch,
-
Hideki Garren,
Chief Medical Officer -
David A Ford,
Chief People Officer